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Abstract
Chronic cavitary pulmonary aspergillosis (CCPA) is a progressive lung condition with a 10–30% annual mortality. Although overtly
immunocompetent, some immunogenetic defect in patients is likely. To investigate a possible immunogenetic defect in CCPA, we analysed
biologically plausible candidate genes in 112 CCPA patients and 279 healthy controls in a genetic association study of genes involved in the
post-recognition immune response to Aspergillus fumigatus. We also compared gene expression in monocyte-derived macrophages from
subjects with and without disease, both at baseline and during stimulation with A. fumigatus. Compared with macrophages from healthy
subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of
expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15
(n = 3). Uncontrolled expression of IL1 and IL6 and continuing high levels of these cytokines may result in continuing cellular inﬂux and
pro-inﬂammatory responses, inhibiting disease resolution and contributing to disease progression in CCPA. The association of SNPs in IL1B,
IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.
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Introduction
Estimates suggest that humans inhale several hundred Asper-
gillus fumigatus conidia each day, which persist in the lung [1,2].
Most individuals do not suffer symptoms, but in a small
minority this fungus causes the serious disease chronic cavitary
pulmonary aspergillosis (CCPA) [3]. Affected individuals
almost invariably have some prior lung disease (e.g. chronic
obstructive pulmonary disorder (COPD) or pulmonary tuber-
culosis (TB)) but are overtly immunocompetent and do not
generally have a clinical history of recurrent infection [4].
CCPA involves the formation and/or expansion of a pulmonary
cavity/cavities over months or years, with progressive lung
ﬁbrosis and chronic inﬂammation [3]. Aspergillus growth on the
cavity surface, without tissue invasion, may lead to fungal balls
(aspergillomas). The mechanisms underlying the observed
pathology are largely unknown, but development of aspergil-
loma(s) represents a later phase of CCPA [5].
The human immune response to A. fumigatus involves
macrophages and neutrophils, which ingest and kill the fungus
and induce pro-inﬂammatory cytokines and cellular inﬂux [6–
8]. As the numerically dominant cell in alveoli, macrophages
are likely to be the ﬁrst innate immune cell to contact invading
fungal particles. Following recognition, a wide variety of
cytokines and chemokines are expressed, including many in
the interleukin-1 (IL1) pathway [9]. Th1 responses appear
beneﬁcial and uncontrolled Th2 responses detrimental
[6,7,10].
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Despite knowledge of the immune response to A. fumigatus,
little is known about the factors affecting susceptibility,
continuing inﬂammation or disease pathogenesis in CCPA.
The most commonly cited susceptibility factor is underlying
disease; however, the proportion of patients with any one
disease is very small, and only a small percentage of individuals
with any one underlying disease develop CCPA [4]. Previous
genetic association studies involving small numbers of patients
have identiﬁed associations between CCPA and TNF, MBL2,
TGFB1, IL15, TLR4 and IL10, [11–14] but do not explain all
cases of CCPA and have proved difﬁcult to replicate. The aim
of the current study was to comprehensively genotype a broad
panel of single nucleotide polymorphisms (SNPs) from genes
important in the post-recognition immune response to
A. fumigatus, in a candidate gene association study involving a
large cohort of patients and healthy controls. We also
investigated whether some of these genes, particularly those
in the IL1 pathway, were differentially expressed by mono-
cyte-derived macrophages (MDMs) from subjects with and
without disease, at baseline and during culture with A. fumigatus.
Methods
See (Appendix S1) for further details.
Subjects
CCPA subjects and healthy controls are deﬁned in Table 1.
CCPA subjects complicated by allergic bronchopulmonary asper-
gillosis (ABPA) were excluded. CCPA subjects were recruited
from the National Aspergillosis Centre (University Hospital of
South Manchester, UK) between March 2006 and August 2010.
Previously recruited healthy subjects were used [15]. The
study was approved by the Local Research Ethics Committee
and written informed consent was obtained from all subjects.
DNA and PBMC extraction from blood
DNA was extracted using a phenol chloroform extraction
method. Peripheral blood mononuclear cells (PBMCs) were
extracted using a Ficoll-paque Plus (GE Lifesciences, Bucking-
ham, UK) density gradient.
Macrophage-Aspergillus fumigatus co-culture
PBMCs were plated onto 24-well plates (2 9 106/well).
Monocytes were selected using 1.5 h plastic adherence.
Monocyte-derived macrophages (MDMs) were generated
using GM-CSF and 15 days incubation. Live A. fumigatus
conidia were added (4 9 105/well). RNA was extracted using
the RNeasy kit (Qiagen Ltd, Crawley, UK).
Measuring expression by MDMs
Gene expression was measured in pooled RNA samples (1 lg)
from each disease group (n = 10 subjects) using the human
innate and adaptive immune responses RT2 proﬁler PCR array
(SABiosciences, Qiagen Ltd, Crawley, UK). The housekeeping
genes HRPT1, RPL13A and GAPDH were used as the normaliser
genes. Data were analysed using the manufacturer’s online
RT-PCR data analysis tool (http://pcrdataanalysis.sabiosciences.
com/pcr/arrayanalysis.php) to calculate fold changes relative to
the healthy average 0 h.
Gene and SNP selection, genotyping, quality control and data
analysis
Seventeen biologically plausible and/or previously associated
candidate genes were selected (Table S1). Haplotype tagging
SNPs (n = 327) were selected using the Genome Variation
Server (http://gvs.gs.washington.edu/GVS/) and genotyping of
168 of these was completed on the Sequenom (Sequenom
Inc., San Diego, CA, USA). After quality control and exclusion
of SNPs redundant or monomorphic within our population,
137 SNPs remained for analysis using Stata (Statacorp, College
Station, TX, USA). Logistic regression was used to determine
association using dominant and recessive models. Correction
for multiple testing was completed using the Benjamini-
Hochberg correction for False Discovery Rate (FDR).
Statistical analysis
Statistical analysis was completed in Stata, SPSS (Version 16;
SPSS Inc., Chicago, IL, USA) and GraphPad Prism (Version
5.02; GraphPad Software Inc., La Jolla, CA, USA). Ages and
percentage of male subjects were compared between the
TABLE 1. Diagnostic criteria for recruited subjects
Disease Diagnostic criteria
CCPA All the following are required:
Chronic pulmonary or systemic symptoms (3 months) compatible
with CCPA, including at least one of: weight loss, productive
cough or haemoptysis
Cavitary pulmonary lesion with evidence of paracavitary inﬁltrates
or expansion of cavity size over time
Either positive serum Aspergillus precipitins test or isolation of
Aspergillus from pulmonary or pleural cavity
Elevated inﬂammatory markers (C-reactive protein, plasma viscosity
or erythrocyte sedimentation rate)
No overt immunocompromising conditions (HIV infection,
leukaemia, chronic granulomatous disease, etc.)
No concurrent ABPA
Further indicators:
Often multiple cavities, with more forming over time if untreated
A fungal ball or aspergilloma may or may not be present
Healthy
control
All the following are required:
No diagnosis of asthma
No diagnosis of aspergillosis
Negative SPT (at 3 mm cut-off) and/or IgE (<0.4) to all allergens
tested, including mite, cat, dog and grasses
Negative SPT (at 3 mm cut-off) and/or IgE (<0.4) to all fungi
tested, including Alternaria alternata, Candida albicans, Cladosporium
herbarum, Penicillium chrysogenum (notatum), Trichophyton
rubrum and A. fumigatus
CCPA, chronic cavitary aspergillosis;ABPA, allergic bronchopulmonary aspergillosis.
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groups using Mann–Whitney tests as the data were not
normally distributed. For analysis of expression data, statistical
analysis using t-test, repeated measures one-way ANOVA and
two-way ANOVA was completed using GraphPad.
Results
Characteristics of the study population
In total, 116 Caucasian subjects with CCPA were recruited. A
further 280 healthy Caucasian subjects were selected as
controls. Of these, 112 CCPA and 279 healthy subjects were
genotyped successfully. Most CCPA patients had some, and
many had multiple, underlying diseases (Table 2). The CCPA
group was older (median age 64.9 years vs. 47.0 years,
p <0.0001) and more likely to be male (60.7% vs. 40.1%, p
0.0005) than the healthy group (Table 2). Characteristics were
similar in the subset of subjects used for gene expression
experiments (Table 2) and are likely to be representative of
the total study population.
Expression of the IL1pathway differs between MDMs from
CCPA subjects and healthy subjects
The pattern of expression of IL1A and IL1B showed a
markedly different time course in CCPA patients compared
with healthy controls. For healthy controls, expression
peaked by 3 h and returned to baseline by 6 h. In CCPA
patients there was a much slower increase in expression,
which continued to 9 h (Fig. 1). Expression of the down-
stream signalling molecules IRAK2 and TRAF6 initially rose in
both groups, then fell below baseline after 6 h in the healthy
group but not the CCPA group (TRAF6 does reduce after
6 h in the CCPA group, but not to below baseline) (Fig. 1).
Expression of the negative regulator, IL1RN, increased in both
groups after stimulation with A. fumigatus (Fig. 1). Expression
of IL6 follows a similar pattern to IL1A and IL1B (Fig. 1).
Additional results from the IL1 pathway are presented in
Figure S1. Expression of the anti-inﬂammatory cytokine TGFB1
does not change over time in CCPA group, but increases in
the healthy group at 9 h.
Genetic association in CCPA
Of the 137 SNPs that passed quality control, seven SNPs in
four genes were found to be associated with CCPA (p <0.05).
Five remained signiﬁcant after correction for multiple testing
(Table 3), including three intronic mutations in IL15
(rs6842735, rs12508866 and rs1519551), an intronic inser-
tion-deletion mutation in IL1B (rs3917354) (Fig. 2) and a 3′
UTR SNP in IL1RN (rs4252041). Additional SNPs in IL17A and
IL1B showed trends towards signiﬁcance but failed to pass
TABLE 2. Characteristics of patients and controls
Characteristic
Genetic association study Gene expression study
CCPA Healthy CCPA Healthy
n 112 279 10 10
Age (years) (median, IQR) 64.9 (59.4–70.8) 47.0 (44.2–50.5) 59.0 (55.8–68.9) 38.0 (31.2–51.1)
% Male 60.7 40.1 70 (7/10) 40 (4/10)
Positive Aspergillus culture (%) 23.2 (26/112) N/A 50 (5/10) N/A
A. fumigatus 92.3 (24/26) N/A 100 (5/5) N/A
Aspergillus niger 3.8 (1/26) N/A 0 (0/5) N/A
Other Aspergillus spp. 3.8 (1/26) N/A 0 (0/5) N/A
CCPA type (%)
CCPAaspergilloma 60.7 (68/112) N/A 40 (4/10) N/A
CCPA + aspergilloma 39.3 (44/112) N/A 60 (6/10) N/A
Bronchiectasisa (%) 25.9 (29/112) N/A 30 (3/10) N/A
Underlying disease (%)
COPD and/or emphysema ( bullae) 44.6 (50/112) N/A 30 (3/10) N/A
Pneumoniab (previous) 20.5 (23/112) N/A 30 (3/10) N/A
Pneumothorax (previous,  bullae) 20.5 (23/112) N/A 20 (2/10) N/A
Thoracic surgery (previous) 19.6 (22/112) N/A 20 (2/10) N/A
Classical tuberculosis (TB, previous) 17.9 (20/112) N/A 20 (2/10) N/A
Non-tuberculous mycobacterial infection
(atypical TB, previous)
12.5 (14/112) N/A 10 (1/10) N/A
Lung cancer survivor 11.6 (13/112) N/A 10 (1/10) N/A
Asbestos exposure/asbestosis (previous) 10.7 (12/112) N/A 10 (1/10) N/A
Asthma 8.9 (10/112) N/A 0 (0/10) N/A
Sarcoidosis 8.0 (9/112) N/A 20 (2/10) N/A
Other 5.4 (6/112)c N/A 10 (1/10)d N/A
Rheumatoid arthritise 4.5 (5/112) N/A 0 (0/10) N/A
Ankylosing spondylitis/kyphoscoliosis 3.6 (4/112)f N/A 0 (0/10) N/A
No underlying disease identiﬁed 1.8 (2/112) N/A 0 (0/10) N/A
IQR, interquartile range.
aBronchiectasis is considered a co-existent rather than underlying disease in CCPA.
bCommunity-acquired pneumonia requiring hospitalization.
cIncludes alcohol excess (3), chest radiotherapy without lung cancer (1), dextrocardia (1) and smoke inhalation (1).
dIncludes alcohol excess (1).
eRheumatoid arthritis patients were receiving <7.5 mg/day prednisolone and were therefore considered immunocompetent.
fAnkylosing spondylitis (1), kyphoscoliosis (3). COPD, chronic obstructive pulmonary disorder.
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correction for multiple testing (FDR-corrected p-values 0.050–
0.051) (Table 3).
An IL10 SNP (rs1800896) previously associated with
invasive aspergillosis (IA) was not associated with CCPA and
a previous association with CCPA (MBL2 rs5030737) could
not be replicated (Table S2).
Discussion
Knowledge of the immune responses that are defective in
CCPA is very limited, but is essential if we are to develop
novel treatments for this progressive, often fatal, lung
(a) (b)
(c) (d)
(e) (f)
(g)
FIG. 1. Expression of the IL1 pathway differs between MDMs from CCPA (open circles) and healthy subjects (closed squares).
Fold difference is calculated relative to the healthy 0 h. p-values indicate the differences in the change over time between the two
groups, calculated by repeated measures two-way ANOVA. Each group comprises ten pooled RNA samples. Mean and standard
deviations are shown for the three replicates completed.
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condition. Identiﬁcation of genetic susceptibility patterns may
facilitate stratiﬁcation of at-risk individuals, and possible
disease prevention, or at least earlier diagnosis. We have
shown that following stimulation of MDMs with live A. fu-
migatus, expression of cytokines from the IL1 pathway is
markedly different in patients with CCPA compared with
healthy controls. In addition, we identiﬁed SNPs in this
pathway (as well as SNPs in IL15) that are associated with
CCPA. This is the ﬁrst study to investigate the possible
underlying mechanisms of CCPA by comparing in vitro effects
of A. fumigatus on MDMs from CCPA patients and healthy
subjects; previous studies were conducted only in cells from
healthy donors [6,7,9,16]. Further, this is by far the most
extensive genetic association study of CCPA to date,
involving three times as many patients and investigating many
more SNPs.
TABLE 3. SNPs associated with chronic cavitary pulmonary aspergillosis (CCPA)
Gene SNP
Alleles
(M/m)
Model for
association
Genotype frequency
Odds ratio
(95% CI) p-value
FDR
p-value LocationGenotype CCPA (%) Healthy (%)
IL1RN rs4252041 C/T TT + TC vs. CC CC TT+TC 109 (97.3) 3 (2.7) 249 (89.2) 30 (10.8) 0.23 (0.07, 0.76) 0.017 0.039 3’UTR
IL1B rs3136558 A/G AG + GG vs. AA AA AG + GG 82 (73.2) 30 (26.8) 170 (60.9) 109 (39.1) 0.57 (0.35, 0.92) 0.023 0.051 Intronic
rs3917354 T/- T-+-- vs. TT TT T-+-- 86 (76.8) 26 (23.2) 180 (64.5) 99 (35.5) 0.55 (0.33, 0.91) 0.020 0.046 Intronic
IL15 rs1519551 A/G AA + AG vs. GG GG AA + AG 34 (30.9) 76 (69.1) 48 (17.6) 225 (82.4) 0.48 (0.29, 0.79) 0.004 0.011 Intronic
rs6842735 G/T TT + GT vs. GG GG TT + GT 69 (62.7) 41 (37.3) 205 (75.1) 68 (24.9) 1.79 (1.12, 2.88) 0.016 0.038 Intronic
rs12508866 T/C CC + TC vs. TT TT CC + TC 55 (50) 55 (50) 172 (63.0) 101 (37.0) 1.70 (1.09, 2.66) 0.020 0.046 Intronic
IL17A rs3748067 G/A AA + GA vs. GG GG AA + GA 85 (75.9) 27 (24.1) 239 (85.7) 40 (14.3) 1.90 (1.10, 3.28) 0.022 0.050 3’UTR
CI, conﬁdence interval; M/m, Major allele/minor allele.
p-value calculated for the model indicated using logistic regression in Stata. Risk allele shown in bold. SNPs in bold remain signiﬁcant after Benjamini-Hochberg adjustment for false
discovery rate (FDR adjusted p-values shown).
(a) (b)
(c)
(e)
(d)
FIG. 2. Genotype frequencies of SNPs associated with CCPA; 279 healthy subjects and 112 CCPA subjects were genotyped successfully.
RS3917354 is an insertion-deletion mutation.
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We found that after exposing MDMs to A. fumigatus,
expression of IL1A and IL1B peaks at 3 h for healthy subjects,
then falls to baseline, whereas for CCPA subjects, expression
rises more slowly but is still rising at 9 h (the experiment
duration); it is unclear whether this represents the peak
response. The reason that expression of these pro-inﬂamma-
tory cytokines follows such different time courses in health
and disease is unclear. In our co-culture model, live A. fumig-
atus conidia were introduced; until 3 h the predominant
morphology was conidia, by 6 h germtubes and by 9 h almost
completely hyphae (Appendix S2, Figure S2). The observed
expression proﬁles suggest an initial pro-inﬂammatory IL1
response to the presence of conidia by MDMs from healthy
subjects, followed by a reducing inﬂammatory response at 6–
9 h as germtubes and hyphae predominate. It is likely in health
that other immune cells (e.g. neutrophils) are recruited to
clear fungus if macrophages fail [6], and we speculate that
down-regulation of IL1 expression prevents a damaging
on-going inﬂammatory response. For CCPA patients, the IL1
response during the ﬁrst 3 h (when conidia predominate) was
comparatively muted but continued to rise during the germ-
tube and hyphal phases, which may reﬂect a lack of/delayed
response to the changing fungal morphology (or the length of
fungal exposure), which may result in on-going inﬂammation,
resulting in tissue damage. The expression proﬁles of IRAK2,
TRAF6 and IL6 also appear delayed in the CCPA group. These
molecules are involved in multiple pathways, one of which is
the IL1 pathway, where they are found downstream of IL1
itself. Although the expression may not be entirely related to
the IL1 pathway, which could explain the differences between
the TRAF6 and IRAK2 expression, the observed patterns
appear to show a similar, delayed response in the CCPA group
compared with the healthy group. In addition, expression of
IL1 receptor accessory protein (IL1RAP) is also increased in
the CCPA group compared with the healthy group at 9 h
(Figure S1). This protein forms a complex with the IL1
receptor and IL1 at the cell surface, and is required for the
response to IL1. Its expression correlates with IL1 respon-
siveness, including the IL1-induced production of inﬂammatory
and immune responses [17,18]. We speculate that continued
production of IL1 (in particular IL1b) could result in sustained
cellular recruitment, proliferation and activation, and contin-
ued inﬂammation via both the IL1 pathway and IL17, which
could promote CCPA disease progression rather than reso-
lution.
IL1b is a key cytokine secreted and activated by the NLRP3
inﬂammasome following stimulation by pathogens including
A. fumigatus [19]. IL1b is essential for the induction and
expansion of the highly pro-inﬂammatory human Th17 cells
[20], and can induce pulmonary inﬂammation via IL17 [21].
This is likely to be initially beneﬁcial, and several studies
(usually with a single time-point) have demonstrated that
expression of the IL1 pathway (IL1a, IL1b and IL6) is increased
in cells (macrophages and monocytes) from healthy donors in
response to A. fumigatus [6,7,9]. However, uncontrolled IL1b
can be detrimental and has been implicated in multiple
diseases, including diabetes and gout [22]. Because of the
presumed damaging effects, IL1b-targeted therapies have been
attempted in several diseases [22]. For example, in arthritis,
where IL1b is pivotal for sustained cellular recruitment and
erosive cartilage damage [23], IL1b-targeted therapies reduce
large joint inﬂammation and corticosteroid dosage [24].
Furthermore, in a mouse model, IL1 inhibition reduces levels
of inﬂammatory cytokines (including IL6 and IL1b) and joint
inﬂammation [25].
The possible delayed response and failure to control
inﬂammation observed in the CCPA group may be inﬂuenced
by TGFB1 expression. TGF-b is an anti-inﬂammatory cytokine,
which has previously been shown to antagonise IL1-mediated
effects, such as cartilage proteoglycan synthesis in arthritic
mice and lymphocyte proliferation [26]. This can occur via
down-regulation of IL2-mediated proliferative signals. As IL2
stimulates production of IL1 [27], TGF-b may reduce levels of
IL1 via IL2. In the current study, TGFB1 expression increases
at 9 h in the healthy group but not the CCPA group. This
increased expression may be important in controlling an
IL1-induced inﬂammatory response, and the low level in the
CCPA group may represent a deﬁciency, which may contrib-
ute to uncontrolled inﬂammation in these subjects. TGF-b is
also known to mediate ﬁbrosis, and as such increased levels
may be expected in CCPA patients as lung ﬁbrosis is a feature
of uncontrolled CCPA. This was not seen, and may reﬂect
the short time course or that non-TGF-b-driven processes
are involved in ﬁbrosis in CCPA. The differential gene
expression observed between the healthy and CCPA groups
appears to suggest a mechanism by which disease develops
and progresses as a result of continued IL1 production and
continued inﬂammation. An alternative view would be that
the observed increased expression of IL1 and other genes is
due to the CCPA, rather than a cause of it. Innate immune
cells such as monocytes do have an adaptive or memory
component [28]; however, the MDMs used in this study are
stored as frozen cells before being cultured for 15 days, and
whether this memory would be retained is unclear. Despite
this, it is possible that the response to A. fumigatus is a
learned response rather than a predetermined response and
as such that the differential response is a result of CCPA
rather than a cause of susceptibility. However, the association
of SNPs in this pathway with CCPA supports the theory that
these genes are involved in susceptibility.
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In addition to the gene expression observations, we
identiﬁed SNPs in the IL1 pathway associated with CCPA.
Previously, a haplotype including polymorphisms in IL1RN and
IL1B was associated with susceptibility to IA [29]. The IL1B
SNP associated with CCPA (rs3917354) in the current study is
an intronic single base deletion that has previously been
associated with ankylosing spondylitis [30]. One CCPA patient
had underlying ankylosing spondylitis, but as this patient
constituted only 0.9% of the patient population we do not
feel this unduly inﬂuenced our results. Traditionally, intronic
regions are considered non-functional; however, the
ENCODE project suggests these regions could indeed be
functional, and as such this SNP, or those in linkage disequi-
librium (LD) with it, may affect the function of IL1b and in turn
susceptibility to CCPA [31].
The IL1RN SNP associated with CCPA (rs4252041) is
located in the 3’UTR. The CC genotype has previously been
associated with higher circulating IL1Ra levels but only in
patients with previous myocardial infarction (3 months to
6 years previously) and whether the higher levels had an effect
(beneﬁcial or detrimental) was not investigated [32]. A 3’UTR
SNP in IL17A (rs3748067) was also found to be associated with
CCPA, and although this SNP did not quite pass correction for
multiple testing (FDR-adjusted p-value 0.050), it is interesting
because of the interplay between IL1 and IL17. As mentioned,
IL1b is essential for both the induction and expansion of Th17
cells [20]. These cells are highly pro-inﬂammatory. In addition,
IL1b can induce pulmonary inﬂammation via IL17 [21]. As
discussed, inﬂammation may be initially beneﬁcial but longer
term could be detrimental, and a failure to control this
response could result in damaging inﬂammation in CCPA.
Although we have not analysed expression of IL17 in the
current study, the identiﬁcation of associated SNPs in this gene
suggests a role for IL17 in susceptibility to CCPA.
Three intronic SNPs in IL15 are also signiﬁcantly associated
with CCPA. These SNPs were not in high LD with each other
(all pairs r2 ≤ 0.36), their function remains unknown and none
has been previously associated with disease, although another
SNP in IL15 (not included in our study) has previously been
shown to be associated with non-invasive aspergillosis [13].
We did not measure IL15 expression; however, other studies
have shown that IL15 increases the oxidative burst, IL8 release
and hyphal damage of cells in response to A. fumigatus [33].
IL15 can act on dendritic cells (DCs), T-cells and macrophages
and appears to promote IFN-c expression and augment a Th1
response [34,35]. Th1 responses are thought to be beneﬁcial
in infections with A. fumigatus, and impaired IFN-c responses
are associated with aspergillosis, including chronic pulmonary
aspergillosis [6,7,10,36,37]. This combined evidence supports a
role for IL15 as beneﬁcial in the response to A. fumigatus, and
suggests that SNPs that affect functionality or expression of
IL15 may increase susceptibility to CCPA.
As in a previous study by our group [38], we could not
replicate an association of MBL2 with CCPA [12]. MBL2 may
be associated with CCPA complications, severity and disease
progression, rather than with CCPA itself [38] (Appendix S3).
In the gene expression experiments we used pooled
samples, as this allowed us to measure an increased number
of cytokines from the limited number of cells available for each
individual patient. Although pooling resulted in us being unable
to view the distribution of individual data points for each
cytokine and measure interpatient variability, it is unlikely that
had we analysed samples individually and calculated a mean
value for cases and for controls these would have been
materially different from the pooled values. We acknowledge
that it is possible that the expression level measured in the
pooled samples could be skewed by a few individuals, but we
nevertheless believe our data indicate that the IL1 pathway is
involved in CCPA, at least in certain individuals, and merits
further, more detailed, investigation. We recognize the ideal
cell type for these experiments is the alveolar macrophage;
however, had we recruited only subjects ﬁt enough for
bronchoscopy, the population would have been skewed
towards stable patients at the mild end of the CCPA spectrum.
In addition, we acknowledge that while the adherence method
is a recognized method of selecting for monocytes, a number
of lymphocytes may remain present in the culture.
Although our study recruited only 112 patients with CCPA,
we emphasize that this is the largest genetic study of CCPA to
date. The disease is relatively rare in developed countries; this
population was recruited from the National Aspergillosis
Centre, which receives referrals from across the UK. Selection
of a control population was challenging; the range of underlying
conditions in CCPA patients is broad and patients usually have
multiple co-morbidities [4]. Recruiting matched controls with
the same underlying diseases for every case would be ideal, but
practically impossible, as demonstrated by the fact that all
previous genetic association studies involving CCPA have used
healthy controls [11,12,14]. We therefore selected healthy
unmatched controls, recognizing that this reduces rather than
increases our power to ﬁnd genetic associations with CCPA
and as such does not invalidate our ﬁndings. It could be argued
that the associations we ﬁnd are related to an underlying
disease rather than to CCPA. This is unlikely, as each underling
disease occurs in only a small proportion of cases; however, to
investigate this we compared the results of our study with
genetic studies of TB, the commonest primary underlying
disease in CCPA [4] (Appendix S4). Although SNPs in genes
we studied have been previously associated with TB, none of
these were associated with CCPA, suggesting lack of matching
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for previous TB did not affect the observed associations. We
acknowledge that because our control population is younger
than the patient population some could develop CCPA later in
life; again, this would reduce, not increase, our power to
identify associations.
In conclusion, our data indicate that expression of the IL1
pathway differs in CCPA compared with health, and that
genetic variants in this pathway are associated with disease.
We speculate that ongoing expression of IL1B (and IL6) may
result in continuing inﬂammation, inhibiting disease resolution
and contributing to disease progression in CCPA. As our
study is relatively small, these ﬁndings need conﬁrmation, but
this pathway merits further study in this disease. CCPA is a
serious and debilitating chronic condition, which requires
long-term treatment with potentially toxic and often expen-
sive antifungal agents and we hope that increased under-
standing of the genes and pathways involved in both
susceptibility and disease progression in CCPA will lead to
novel treatments and improved identiﬁcation of at-risk
individuals.
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